BB ACT
Alternative Names: BB-ACTLatest Information Update: 22 May 2024
At a glance
- Originator Bespoke Biotherapeutics
- Class Antineoplastics; Cell therapies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 30 Apr 2024 Early research in Cancer in USA (Parenteral), prior to April 2024 (Bespoke Biotherapeutics pipeline, April 2024)